nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2018-1-95-101nnp-892Research ArticleREVIEWSОБЗОРЫEffects of some commonly used drugs on cognitive functionsВлияние некоторых широко применяемых лекарственных средств на когнитивные функцииОстроумоваО. Д.OstroumovaO. D.

Контакты: Ольга Дмитриевна Остроумова

Кафедра клинической фармакологии и пропедевтики внутренних болезней лечебного факультета Сеченовского университета; кафедра факультетской терапии и профболезней МГМСУ им. А.И. Евдокимова 119991, Москва, ул. Трубецкая, 8, стр. 2

Department of Clinical Pharmacology and Internal Propedeutics, Faculty of General Medicine, Sechenov University; Department of Intermediate-Level Therapy and Occupational Diseases, A.I. Evdokimov Moscow State University of Medicine and Dentistry

8, Trubetskaya St., Build. 2, Moscow 119991

ostroumova.olga@mail.ruШихЕ. В.ShikhE. V.

Department of Clinical Pharmacology and Internal Propedeutics, Faculty of General Medicine

8, Trubetskaya St., Build. 2, Moscow 119991

РеброваЕ. В.RebrovaE. V.

Кафедра клинической фармакологии и пропедевтики внутренних болезней лечебного факультета 

119991, Москва, ул. Трубецкая, 8, стр. 2

Department of Clinical Pharmacology and Internal Propedeutics, Faculty of General Medicine

8, Trubetskaya St., Build. 2, Moscow 119991

АбросимовА. Г.AbrosimovA. G.

Кафедра клинической фармакологии и пропедевтики внутренних болезней лечебного факультета 

119991, Москва, ул. Трубецкая, 8, стр. 2

Department of Clinical Pharmacology and Internal Propedeutics, Faculty of General Medicine

8, Trubetskaya St., Build. 2, Moscow 119991

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский университет)» Минздрава России; ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава РоссииРоссияI.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia; A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of RussiaRussian FederationФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский университет)» Минздрава РоссииРоссияI.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaRussian Federation20182406201810295101Copyright © Ostroumova O.D., Shikh E.V., Rebrova E.V., Abrosimov A.G., 20182018Остроумова О.Д., Ших Е.В., Реброва Е.В., Абросимов А.Г.Ostroumova O.D., Shikh E.V., Rebrova E.V., Abrosimov A.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/892

The paper discusses the effects of drugs from different pharmacological groups on cognitive functions. It details the impact of drugs used to treat nervous system, cardiovascular, gastrointestinal, respiratory, and endocrine diseases on cognitive functions. It is emphasized that many drugs exert both negative and (less frequently) positive effect on cognitive functions, but it is especially pronounced in drugs used to treat nervous system diseases. There is evidence suggesting that different representatives of a number of pharmacological groups have no class effect on cognitive functions.

Обсуждается действие лекарственных средств (ЛС) различных фармакологических групп на когнитивные функции. Подробно рассмотрено влияние на когнитивные функции препаратов для лечения заболеваний нервной системы, сердечно-сосудистой системы, желудочно-кишечного тракта, дыхательной и эндокринной систем. Подчеркивается, что как негативное, так и (реже) позитивное влияние на когнитивные функции отмечается у многих ЛС, но особенно выражено оно у препаратов, применяемых для лечения заболеваний нервной системы. Приведены данные, свидетельствующие об отсутствии класс-эффекта в отношении когнитивных функций у различных представителей ряда фармакологических групп. 

когнитивные функциилекарственные средстваcognitive functionsdrugsReferencesLezak MD. Neuropsychology assessment. N.Y. University Press; 1983. 768 p.Lezak MD. Neuropsychology assessment. N.Y. University Press; 1983. 768 p.Захаров ВВ. Когнитивные нарушения в неврологической практике. Трудный пациент. 2005;3(5):4-9..Захаров ВВ. Когнитивные нарушения в неврологической практике. Трудный пациент. 2005;3(5):4-9..Diagnostic and statistical manual of mental diseases. V ed. (DSM-V). London: American Psychiatric Association; 2013. 358 p.Diagnostic and statistical manual of mental diseases. V ed. (DSM-V). London: American Psychiatric Association; 2013. 358 p.Гимоян ЛГ, Силванян ГГ. Нарушение когнитивных функций: актуальность проблемы, факторы риска, возможности профилактики и лечения. Архив внутренней медицины. 2013;2(10):35-40. [Gimoyan LG, Silvanyan GG. Infringement of cognitive functions: an urgency of a problem, risk factors, possibilities of preventive maintenance and treatment. Arkhiv vnutrennei meditsiny. 2013;2(10):35-40. (In Russ.)].Гимоян ЛГ, Силванян ГГ. Нарушение когнитивных функций: актуальность проблемы, факторы риска, возможности профилактики и лечения. Архив внутренней медицины. 2013;2(10):35-40. [Gimoyan LG, Silvanyan GG. Infringement of cognitive functions: an urgency of a problem, risk factors, possibilities of preventive maintenance and treatment. Arkhiv vnutrennei meditsiny. 2013;2(10):35-40. (In Russ.)].Prince M, Bryce R, Albanese E, et al. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013 Jan;9(1):63-75.e2. doi: 10.1016/j.jalz.2012.11.007.Prince M, Bryce R, Albanese E, et al. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013 Jan;9(1):63-75.e2. doi: 10.1016/j.jalz.2012.11.007.Nevado-Holgado AJ, Kim CH, Winchester L, et al. Commonly prescribed drugs associate with cognitive function: a crosssectional study in UK Biobank. BMJ Open. 2016 Nov 30;6(11):e012177. doi: 10.1136/bmjopen-2016-012177.Nevado-Holgado AJ, Kim CH, Winchester L, et al. Commonly prescribed drugs associate with cognitive function: a crosssectional study in UK Biobank. BMJ Open. 2016 Nov 30;6(11):e012177. doi: 10.1136/bmjopen-2016-012177.Парфенов ВА. Дисциркуляторная энцефалопатия и сосудистые когнитивные расстройства. Москва: ИМА-ПРЕСС; 2017. 128 с.Парфенов ВА. Дисциркуляторная энцефалопатия и сосудистые когнитивные расстройства. Москва: ИМА-ПРЕСС; 2017. 128 с.Tedesco MA, Ratti G, Mennella S, et al. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens. 1999 Nov;12(11 Pt 1):1130-4.Tedesco MA, Ratti G, Mennella S, et al. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens. 1999 Nov;12(11 Pt 1):1130-4.Fogari R, Mugellini A, Zoppi A, et al. Influence of losartan and atenolol on memory function in very elderly hypertensive patients. J Hum Hypertens. 2003 Nov;17(11):781-5. doi: 10.1038/sj.jhh.1001613.Fogari R, Mugellini A, Zoppi A, et al. Influence of losartan and atenolol on memory function in very elderly hypertensive patients. J Hum Hypertens. 2003 Nov;17(11):781-5. doi: 10.1038/sj.jhh.1001613.Katada E, Uematsu N, Takuma Y, et al. Comparison of effects of valsartan and amlodipine on cognitive functions and auditory p300 event-related potentials in elderly hypertensive patients. Clin Neuropharmacol. 2014 SepOct;37(5):129-32. doi: 10.1097/WNF.0000000000000042.Katada E, Uematsu N, Takuma Y, et al. Comparison of effects of valsartan and amlodipine on cognitive functions and auditory p300 event-related potentials in elderly hypertensive patients. Clin Neuropharmacol. 2014 SepOct;37(5):129-32. doi: 10.1097/WNF.0000000000000042.Fogari R, Mugellini A, Zoppi A, et al. Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur J Clin Pharmacol. 2004 Feb;59(12):863-8. Epub 2004 Jan 28.Fogari R, Mugellini A, Zoppi A, et al. Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur J Clin Pharmacol. 2004 Feb;59(12):863-8. Epub 2004 Jan 28.Fogari R, Mugellini A, Zoppi A, et al. Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J Hum Hypertens. 2006 Mar;20(3):177-85.Fogari R, Mugellini A, Zoppi A, et al. Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J Hum Hypertens. 2006 Mar;20(3):177-85.CDC. NCHS. Underlying Cause of Death 1999-2013 on CDC WONDER Online Database. Underlying Cause Death 1999-2013 CDC WONDER Online Database. 2015.CDC. NCHS. Underlying Cause of Death 1999-2013 on CDC WONDER Online Database. Underlying Cause Death 1999-2013 CDC WONDER Online Database. 2015.Schultz BG, Patten DK, Berlau DJ. The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms. Transl Neurodegener. 2018 Feb 27;7:5. doi: 10.1186/s40035-018-0110-3. eCollection 2018.Schultz BG, Patten DK, Berlau DJ. The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms. Transl Neurodegener. 2018 Feb 27;7:5. doi: 10.1186/s40035-018-0110-3. eCollection 2018.Ott BR, Daiello LA, Dahabreh IJ, et al. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. J Gen Intern Med. 2015 Mar;30(3):348-58. doi: 10.1007/s11606-014-3115-3. Epub 2015 Jan 10.Ott BR, Daiello LA, Dahabreh IJ, et al. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. J Gen Intern Med. 2015 Mar;30(3):348-58. doi: 10.1007/s11606-014-3115-3. Epub 2015 Jan 10.Li R, Wang TJ, Lyu PY, et al. Effects of Plasma Lipids and Statins on Cognitive Function. Chin Med J (Engl). 2018 Feb 20;131(4):471-476. doi: 10.4103/03666999.225062.Li R, Wang TJ, Lyu PY, et al. Effects of Plasma Lipids and Statins on Cognitive Function. Chin Med J (Engl). 2018 Feb 20;131(4):471-476. doi: 10.4103/03666999.225062.Рекомендации ЕОК/ЕОА по диагностике и лечению дислипидемий 2016 г. Российский кардиологический журнал. 2017;(5):777. doi.org/10.15829/1560-4071-2017-5-7-77.Рекомендации ЕОК/ЕОА по диагностике и лечению дислипидемий 2016 г. Российский кардиологический журнал. 2017;(5):777. doi.org/10.15829/1560-4071-2017-5-7-77.Harvey PD, Sabbagh MN, Harrison JE, et al. No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data. Eur Heart J. 2018 Feb 1;39(5):374-381. doi: 10.1093/eurheartj/ehx661.Harvey PD, Sabbagh MN, Harrison JE, et al. No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data. Eur Heart J. 2018 Feb 1;39(5):374-381. doi: 10.1093/eurheartj/ehx661.Kirchhof P, Haeusler KG, Blank B, et al. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. Eur Heart J. 2018 Mar 20. doi: 10.1093/eurheartj/ehy176. [Epub ahead of print].Kirchhof P, Haeusler KG, Blank B, et al. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. Eur Heart J. 2018 Mar 20. doi: 10.1093/eurheartj/ehy176. [Epub ahead of print].Stefansdottir H, Arnar DO, Aspelund T, et al. Atrial fibrillation is associated with reduced brain volume and cognitive function independent of cerebral infarcts. Stroke. 2013 Apr;44(4):1020-5. doi: 10.1161/STROKEAHA.12.679381. Epub 2013 Feb 26.Stefansdottir H, Arnar DO, Aspelund T, et al. Atrial fibrillation is associated with reduced brain volume and cognitive function independent of cerebral infarcts. Stroke. 2013 Apr;44(4):1020-5. doi: 10.1161/STROKEAHA.12.679381. Epub 2013 Feb 26.Kirchhof P, Benussi S, Kotecha D, et al. Рекомендации ESC по лечению пациентов с фибрилляцией предсердий, разработанные совместно с EACTS. Российский кардиологический журнал. 2017;(7):7-86. [Kirchhof P, Benussi S, Kotecha D, et al. ESC recommendations for the treatment of patients with atrial fibrillation, developed in conjunction with EACTS. Rossiiskii kardiologicheskii zhurnal. 2017;(7):7-86. (In Russ.)]. doi: 10.15829/15604071-2017-7-7-86.Kirchhof P, Benussi S, Kotecha D, et al. Рекомендации ESC по лечению пациентов с фибрилляцией предсердий, разработанные совместно с EACTS. Российский кардиологический журнал. 2017;(7):7-86. [Kirchhof P, Benussi S, Kotecha D, et al. ESC recommendations for the treatment of patients with atrial fibrillation, developed in conjunction with EACTS. Rossiiskii kardiologicheskii zhurnal. 2017;(7):7-86. (In Russ.)]. doi: 10.15829/15604071-2017-7-7-86.Whiting DR, Guariguata L, Weil C, et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011 Dec;94(3):311-21. doi: 10.1016/j.diabres.2011.10.029. Epub 2011 Nov 12.Whiting DR, Guariguata L, Weil C, et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011 Dec;94(3):311-21. doi: 10.1016/j.diabres.2011.10.029. Epub 2011 Nov 12.IDF atlas (7th edition update). Brussels: International Diabetes Federation; 2015.IDF atlas (7th edition update). Brussels: International Diabetes Federation; 2015.Dedov II, Shestakova MV, Galstyan GR. The prevalence of type 2 diabetes in the adult population of Russia (NATION study). Sakharnyi diabet. 2016;19(2):104-12. (In Russ.).Dedov II, Shestakova MV, Galstyan GR. The prevalence of type 2 diabetes in the adult population of Russia (NATION study). Sakharnyi diabet. 2016;19(2):104-12. (In Russ.).Mansur RB, Lee Y, Zhou AJ, et al. Determinants of cognitive function in individuals with type 2 diabetes mellitus: A meta-analysis. Ann Clin Psychiatry. 2018 Feb;30(1):38-50.Mansur RB, Lee Y, Zhou AJ, et al. Determinants of cognitive function in individuals with type 2 diabetes mellitus: A meta-analysis. Ann Clin Psychiatry. 2018 Feb;30(1):38-50.Adler AI, Shaw EJ, Stokes T, et al. Newer agents for blood glucose control in type 2 diabetes: summary of NICE guidance. BMJ. 2009 May 22;338:b1668. doi: 10.1136/bmj.b1668.Adler AI, Shaw EJ, Stokes T, et al. Newer agents for blood glucose control in type 2 diabetes: summary of NICE guidance. BMJ. 2009 May 22;338:b1668. doi: 10.1136/bmj.b1668.Ng TP, Feng L, Yap KB, et al. Long-Term Metformin Usage and Cognitive Function among Older Adults with Diabetes. J Alzheimers Dis. 2014;41(1):61-8. doi: 10.3233/JAD131901.Ng TP, Feng L, Yap KB, et al. Long-Term Metformin Usage and Cognitive Function among Older Adults with Diabetes. J Alzheimers Dis. 2014;41(1):61-8. doi: 10.3233/JAD131901.Moreira PI. Metformin in the diabetic brain: friend or foe? Ann Transl Med. 2014 Jun;2(6):54. doi: 10.3978/j.issn.2305-5839. 2014.06.10.Moreira PI. Metformin in the diabetic brain: friend or foe? Ann Transl Med. 2014 Jun;2(6):54. doi: 10.3978/j.issn.2305-5839. 2014.06.10.Hsu CC, Wahlqvist ML, Lee MS, et al. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J Alzheimers Dis. 2011;24(3): 485-93. doi: 10.3233/JAD-2011-101524.Hsu CC, Wahlqvist ML, Lee MS, et al. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J Alzheimers Dis. 2011;24(3): 485-93. doi: 10.3233/JAD-2011-101524.Guo M, Mi J, Jiang QM, et al. Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients. Clin Exp Pharmacol Physiol. 2014 Sep;41(9):650-6. doi: 10.1111/1440-1681.12265.Guo M, Mi J, Jiang QM, et al. Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients. Clin Exp Pharmacol Physiol. 2014 Sep;41(9):650-6. doi: 10.1111/1440-1681.12265.Dumbrill JL, Moulton CD. Effects of incretin-based therapies on neurocognitive function in humans: A systematic review of the literature. Prim Care Diabetes. 2018 Feb;12(1): 51-58. doi: 10.1016/j.pcd.2017.06.009. Epub 2017 Jul 18.Dumbrill JL, Moulton CD. Effects of incretin-based therapies on neurocognitive function in humans: A systematic review of the literature. Prim Care Diabetes. 2018 Feb;12(1): 51-58. doi: 10.1016/j.pcd.2017.06.009. Epub 2017 Jul 18.Rizzo MR, Barbieri M, Boccardi V, et al. Dipeptidyl peptidase-4 inhibitor have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment. J Gerontol A Biol Sci Med Sci. 2014 Sep;69(9): 1122-31. doi: 10.1093/gerona/glu032. Epub 2014 Mar 26.Rizzo MR, Barbieri M, Boccardi V, et al. Dipeptidyl peptidase-4 inhibitor have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment. J Gerontol A Biol Sci Med Sci. 2014 Sep;69(9): 1122-31. doi: 10.1093/gerona/glu032. Epub 2014 Mar 26.Isik AT, Soysal P, Yay A, et al. The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer's disease. Diabetes Res Clin Pract. 2017 Jan;123:192-198. doi: 10.1016/j.diabres.2016.12.010. Epub 2016 Dec 21.Isik AT, Soysal P, Yay A, et al. The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer's disease. Diabetes Res Clin Pract. 2017 Jan;123:192-198. doi: 10.1016/j.diabres.2016.12.010. Epub 2016 Dec 21.Mansur RB, Ahmed J, Cha DS, et al. Liraglutide promotes improvement sinMansur RB, Ahmed J, Cha DS, et al. Liraglutide promotes improvement sinObjective measures of cognitive dysfunction in individuals with mood disorders: a pilot, open-label study. J Affect Disord. 2017 Jan 1;207:114-120. doi: 10.1016/j.jad.2016.09.056. Epub 2016 Oct 1.Objective measures of cognitive dysfunction in individuals with mood disorders: a pilot, open-label study. J Affect Disord. 2017 Jan 1;207:114-120. doi: 10.1016/j.jad.2016.09.056. Epub 2016 Oct 1.Aviles-Olmos I, Dickson J, Kefalopoulou Z, et al. Motorand cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease, J Parkinsons Dis. 2014;4(3):337-44. doi: 10.3233/JPD-140364.Aviles-Olmos I, Dickson J, Kefalopoulou Z, et al. Motorand cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease, J Parkinsons Dis. 2014;4(3):337-44. doi: 10.3233/JPD-140364.

The authors declare that there are no conflicts of interest present.